Bayer HealthCare Pharmaceuticals, Inc.

The results of the multicenter, international PROMISE clinical trial demonstrate that gadopiclenol provides similar lesion visualization and contrast enhancement at a gadolinium dose of 0.05 mmol/kg versus a full dose of gadobutrol (0.1 mmol/kg). [i] Bracco has launched gadopiclenol as VUEWAY® (gadopiclenol) solution for injection and VUEWAY® (gadopiclenol) Pharmacy Bulk Package, following the 2022 approval of gadopiclenol by the United States Food and Drug Administration (U.S. FDA). [ii] Gadopiclenol is highly stable and shows the highest relaxivity among the gadolinium-based contrast agents available for clinical use.ii,[iii],[iv],[v],[vi],[vii],[viii] MONROE TOWNSHIP, N.J., July 19, 2023 /PRNewswire/ -- Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, announced today the publication of the PROMISE trial in Radiology.i The PROMISE study was a prospective, multinational, crossover (within-patient), double-blind comparison of the safety and efficacy of 0.05 mmol/kg gadopiclenol (VUEWAY) with 0.1 mmol/kg gadobutrol (Gadavist®) in adult patients referred for contrast-enhanced magnetic resonance imaging (MRI) of head and neck, thorax (including breast), abdomen (including liver, pancreas, and kidneys), pelvis (including ovaries, uterus, and prostate), and musculoskeletal (including extremities). Despite being administered at half the dose of gadobutrol, gadopiclenol provided a comparable degree of contrast enhancement and quality of morphologic assessment of lesions. The type and severity of adverse events (AEs) were similar with the two gadolinium-based contrast agents, with VUEWAY (4.2%) having a slightly lower rate to that of Gadavist (5.5%).i The publication of the results of the PROMISE Study comes on the heels of those of the PICTURE clinical trial, which were published in Investigative Radiology and showed non-inferior quality of morphologic assessment of lesions of the brain and spine with 0.05 mmol/kg VUEWAY compared with 0.1 mmol/kg gadobutrol (Gadavist).[ix] The combined results of the PROMISE and PICTURE trials, and additional clinical evidence, supported the regulatory application for gadopiclenol submitted to the U.S. FDA, resulting in Priority Review and subsequent approval in 2022. Bracco has launched gadopiclenol in the U.S. market as VUEWAY (gadopiclenol) injection and VUEWAY (gadopiclenol) Pharmacy Bulk Package, with a series of hospitals leading first clinical usage. "Before gadopiclenol, most of the GBCAs available for clinical use were indicated for the brain, spine, or central nervous system with narrow indications for the body, such as the breast, liver, and heart,i" said Fulvio Renoldi Bracco, Vice-Chairman and CEO of Bracco Imaging. "The publication of this data reinforces VUEWAY injection as a boundary-pushing and novel MRI contrast agent across the central nervous system (the brain, spine, and surrounding tissues) and body (the head and neck, thorax, abdomen, pelvis, and musculoskeletal system).ii" The PROMISE trial included 273 adult patients suspected of having an enhancing abnormality in one of three different body regions (head/neck, breast/thorax/abdomen/pelvis, or musculoskeletal). Off-site blinded readers with expertise in the respective body regions rated border delineation, internal morphology, and visual contrast enhancement. All primary and secondary endpoints of the study were achieved. For all blinded readers, 0.05 mmol/kg gadopiclenol was non-inferior to 0.1 mmol/kg gadobutrol for all visualization parameters and all readers (P<.001), and superior to unenhanced images (P<.001). Two of three readers yielded higher percentage enhancement for gadopiclenol (P<.001). Lesion-to-background ratio did not differ. For most participants (75%–83%), readers reported no preference between 0.05 mmol/kg gadopiclenol and 0.1 mmol/kg gadobutrol images.i "The results of the PROMISE Study led to the approval of the use of gadopiclenol with MRI of the head and neck, thorax, abdomen, pelvis, and the musculoskeletal system,ii" said Alberto Spinazzi, MD, Chief Medical and Regulatory Officer at Bracco. "Of note, gadopiclenol was approved for both MRI of the central nervous system and of the body at the dose of 0.05 mmol/kg, which showed to provide similar contrast enhancement efficacy compared with a dose of 0.1 mmol/kg of Gadavist. This is thanks to the high relaxivity of gadopiclenol, the highest among all the available GBCAs.ii,iii,IV,V,VI,VII,VIII" VUEWAY injection is a Group II agent within the American College of Radiology's classification of gadolinium-based agents relative to the risk of nephrogenic systemic fibrosis (NSF), indicating association with few if any, unconfounded cases.[x] It is approved for use in adult and pediatric patients aged 2 years and older with magnetic resonance imaging (MRI) of the CNS (brain, spine, and surrounding tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).ii VUEWAY injection is now available to order from Bracco Diagnostics Inc. Visit VUEWAY.com for more information, including its full Prescribing Information. VUEWAY® (gadopiclenol) solution for injection Indications VUEWAY injection is indicated in adults and children aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine and surrounding tissues), the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system). IMPORTANT SAFETY INFORMATION WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF) Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m 2 ), or Acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended VUEWAY dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration. Contraindications VUEWAY injection is contraindicated in patients with history of hypersensitivity reactions to VUEWAY. Warnings Risk of nephrogenic systemic fibrosis is increased in patients using GBCA agents that have impaired elimination of the drugs, with the highest risk in patients with chronic, severe kidney disease as well as patients with acute kidney injury. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. Hypersensitivity reactions, including serious hypersensitivity reactions, could occur during use or shortly following VUEWAY administration. Assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders, administer VUEWAY only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, and observe patients for signs and symptoms of hypersensitivity reactions after administration. Gadolinium retention can be for months or years in several organs after administration. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (brain, skin, kidney, liver and spleen). Minimize repetitive GBCA imaging studies, particularly closely spaced studies, when possible. Acute kidney injury requiring dialysis has occurred with the use of GBCAs in patients with chronically reduced renal function. The risk of acute kidney injury may increase with increasing dose of the contrast agent. Ensure catheter and venous patency before injecting as extravasation may occur, and cause tissue irritation. VUEWAY may impair the visualization of lesions seen on non-contrast MRI. Therefore, caution should be exercised when VUEWAY MRI scans are interpreted without a companion non-contrast MRI scan. The most common adverse reactions (incidence ≥ 0.5%) are injection site pain (0.7%), and headache (0.7%). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please click here for full Prescribing Information for VUEWAY, including BOXED WARNING on Nephrogenic Systemic Fibrosis. Manufactured for Bracco Diagnostics Inc. by Liebel-Flarsheim Company LLC - Raleigh, NC, USA 27616. VUEWAY is a registered trademark of Bracco Imaging S.p.A. All other trademarks and registered trademarks are the property of their respective owners. About Bracco Imaging Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has approximately 3,600 employees and operates in more than 100 markets globally. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. R&D activities are located in four centers based in Italy, Switzerland, the United Kingdom and the United States. Bracco Group global revenues were 1.4 billion Euros in 2020. To learn more about Bracco Imaging, visit . Bracco Diagnostics Inc. Media Relations (USA) Kimberly Gerweck Senior Manager, Marketing Communications [email protected] D: +1 609-524-2777 [i] Kuhl C, Csőszi T, Piskorski W et al. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI Radiology: Volume 308: Number 1—July 2023 [ii] Vueway® (gadopiclenol) solution for injection, 485.1 mg/mL/ Full Prescribing Information and Patient Medication Guide. Monroe Twp., NJ: Bracco Diagnostics Inc.; September 2022. [iii] Robic C, Port M, Rousseaux O, et al. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate with High T1 Relaxivity. Invest Radiol 2019; 54: 475-484. [iv] GADAVIST® (gadobutrol) Injection. Full Prescribing Information and Patient Medication Guide. Bayer HealthCare Pharmaceuticals Inc. Whippany, NJ; April 2022. [v] DOTAREM® (gadoterate meglumine) Injection. Full Prescribing Information. Guerbet LLC. Princeton, NJ. April 2022. [vi] CLARISCAN™ (gadoterate meglumine) injection for intravenous use. Full Prescribing Information and Patient Medication Guide. GE Healthcare. Chicago, IL; February 2020. [vii] ProHance® (Gadoteridol) Injection, 279.3 mg/mL. Full Prescribing Information and Patient Medication Guide. Monroe Twp., NJ: Bracco Diagnostics Inc.; June 2022. [viii] MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL. Full Prescribing Information and Patient Medication Guide. Monroe Twp., NJ: Bracco Diagnostics Inc.; August 2018. [ix] Loevner L, Kolumban B, Hutoczki G, et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System. The PICTURE Randomized Clinical Trial. Invest Radiol. 2022 Dec. [x] American College of Radiology. ACR Manual on Contrast Media. 2023. SOURCE Bracco

Dublin, June 21, 2023 /PRNewswire/ -- The "Radiopharmaceuticals: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Radiopharmaceuticals estimated at US$6.3 Billion in the year 2022, is projected to reach a revised size of US$12.6 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2022-2030. SPECT Radioisotopes, one of the segments analyzed in the report, is projected to record a 8.3% CAGR and reach US$5.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Pet Radioisotopes segment is readjusted to a revised 10% CAGR for the next 8-year period. The U.S. Market is Estimated at $3 Billion, While China is Forecast to Grow at 11.5% CAGR The Radiopharmaceuticals market in the U.S. is estimated at US$3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$836.1 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$757.3 Million by the year 2030. Select Competitors (Total 137 Featured) - Actinium Pharmaceuticals, Inc. Alliance Medical Avid Bioservices Inc Bayer HealthCare Pharmaceuticals Bracco Diagnostics, Inc. Cardinal Health, Inc. GE Healthcare Ion Beam Applications S.A Jubilant Pharma Lantheus Medical Imaging Inc. Medi-Radiopharma Ltd Nordion, Inc. Novartis/Advanced Accelerator Applications Positron Corporation Radiopharm Theranostics Ltd. Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Impact of COVID-19 and a Looming Global Recession 2020: A Year of Disruption & Transformation As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021? World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022 Pandemic-Led Disruptions Affect Radiopharmaceuticals Supply, Hindering Nuclear Medicine Procedures in Several Countries Imaging Screening Volume % Change 1H 2019 Vs 1H 2020 in US Hospitals Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals Struggling with Supply of Medical Radioisotopes Nuclear Medicine Services Limp Back to Normalcy after Easing of COVID-19 Restrictions COVID-19 Presents Generational Opportunity Radiopharmaceuticals - Global Key Competitors Percentage Market Share in 2022 (E) Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2020E Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) An Introduction to Radiopharmaceuticals Mechanism of Action Global Market Prospects & Outlook Key Market Drivers Market Restraints Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance Classification of Radiopharmaceuticals Diagnostic Radiopharmaceuticals: The Dominant Segment Key Drivers Positron Emission Tomography (PET) Single Photon Emission Computed Tomography (SPECT) Therapeutic Radiopharmaceuticals Global Supply Shortages Continue to Challenge Market Growth A Glimpse at Mo-99 Processors Worldwide Nuclear Research Reactor Irradiators Worldwide: A Snapshot Competitive Landscape Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2020 World Brands Recent Industry Activity 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Emergence of Radiotheranostics: Dual-Functioning Radiopharmaceuticals Common Radionuclides Used in Theranostic Applications Radiopharmaceuticals Become Promising for Cancer Theranostics Changing Role of Radiopharmaceuticals in Diagnostic and Therapeutic Applications Advent of New Radiopharmaceuticals Widen Scope Select New Products Startups Develop Unique Radiopharmaceutical Solutions Potential Role of Carbon Dots in Imaging and Theranostics Nano Radiopharmaceuticals: Promising Role in Therapeutic and Imaging Applications Researchers Develop New Nanoparticles to Improve Radiopharmaceutical Efficiency Oncoinvent and NPL Develops Unique Method to Measure & Deliver Dosages in Radiotherapy Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits Select Commercially Available Therapeutic Radiopharmaceuticals Role of Radiopharmaceuticals as Diagnostic Technology PET Eclipses SPECT in Cardiovascular Imaging Worldwide Installed Base of Nuclear Imaging Equipment by Modality, PET Vs SPECT: 2020 Cardiac Amyloidosis Visualization: A Potential Application for PET Innovative Radiopharmaceuticals to Boost Cardiac Applications Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others Radiopharmaceuticals: Direct and Targeted Approach for Cancer Treatment Rising Cancer Incidence Worldwide Spurs Demand Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020 Number of New Cancer Cases and Deaths (in Million) by Region for 2020 Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection Growing Prominence of Therapeutic Radiopharmaceuticals for Cancer Care Rise in Incidence of Neurological Disorders to Drive Growth Application of PET in Drug Development to Expand Opportunities Personalized Medicine Drives Nuclear Medicine Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024 Gallium-68-labeled Radiopharmaceuticals: Production & Administering Challenges Radiopharmaceuticals for COVID-19: Role in Diagnosis, Prognosis, and Therapeutic Uses Arti?cial Intelligence: A Promising Tool in Radiotherapy and Radiopharmaceuticals Aging Global Population: A Vital Demography Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030 Global Cancer Deaths by Age Group (in %) for 2019 Rise in Healthcare Expenditure to Drive Growth World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021 & 2023 Elderly Healthcare Expenditure as a % of GDP in the US, Europe and Japan for 1970, 2010 and 2050 Relevant Aspects of Radiopharmaceutical Production Regulatory Regime Governing Production and Use of Radiopharmaceuticals The Facilitating Innovative Nuclear Diagnostics (FIND) Act, 2021 Challenges Facing Nuclear Medicine Industry 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Accomplished Biotech and Large Pharma Executive to Lead Briquilimab Clinical Development Programs Daniel Adelman, M.D., Appointed to Scientific Advisory Board and as Senior Clinical Advisor REDWOOD CITY, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Edwin J. Tucker as Jasper’s Chief Medical Officer. Concurrently, Jasper also announced the appointment of Dr. Daniel Adelman, who had been serving as Jasper’s Acting Chief Medical Officer, to its Scientific Advisory Board and to the position of Senior Clinical Advisor. “With our clinical program for briquilimab expanding beyond stem cell transplant conditioning into chronic treatment indications such as CSU and LR-MDS, we are thrilled to welcome Edwin to the Jasper leadership team,” said Ron Martell, CEO of Jasper. “Edwin brings an extraordinary depth of clinical and industry experience and a proven track record of leading programs to successful new drug approvals. We look forward to his leadership and contributions as we advance briquilimab toward our next clinical milestones. We are also pleased that we will continue to benefit from Dan Adelman’s guidance in his role on our Scientific Advisory Board as well as our Senior Clinical Advisor for mast cell disease and CSU programs.” “I am excited to be joining the Jasper team during such an important period in the Company’s development,” said Dr. Tucker. “The data derived to date point to the therapeutic potential of briquilimab in chronic mast cell diseases such as urticaria and myelodysplastic syndromes, as well as to its potential as a conditioning agent. Ron and his team have also built a strong organization well-positioned to realize the potential of this asset, and I look forward to contributing my expertise as we advance briquilimab to its next phase of development.” “I am pleased to join everyone at Jasper in welcoming Edwin as Chief Medical Officer, and look forward to working with him to develop briquilimab,” said Dr. Adelman. “Given briquilimab’s unique mechanism of action, I share his passion for the promise this asset has in multiple disease states, and am excited about the well-designed programs Jasper has defined to realize its potential.” Dr. Tucker has over 30 years of clinical experience leading novel drug development. He was most recently Chief Medical Officer at Goldfinch Bio, where he led clinical development and helped build the regulatory, medical affairs and clinical operations functions. Previously, he served as Chief Medical Officer at Mirum Pharmaceuticals, where he contributed to the achievement of key milestones in the development of medicines for adult and pediatric cholestatic liver disease, including the first FDA approval for the treatment of Alagille Syndrome. Prior to joining Mirum, Dr. Tucker held roles of increasing responsibility at Acerta Pharma LLC, now part of the AstraZeneca family of companies, ultimately serving as Chief Operating Officer. During his tenure at Acerta, Dr. Tucker helped create and build the medical safety, quality, compliance and clinical development groups. Prior to joining Acerta, he held leadership positions in development, medical safety and medical affairs at Genentech, Janssen Research and Development and Bayer HealthCare Pharmaceuticals. Dr. Tucker is a member of the Royal College of Physicians (UK), and received his M.B.A. from the University of Connecticut. Dr. Tucker holds degrees in Pharmacology and Medicine from the University of Leeds, United Kingdom. Additionally, he serves as a managing director at Golden Seeds, an investment firm dedicated to pursuing early-stage investment opportunities in women-led businesses. Dr. Adelman has held several leadership roles within the biopharma industry throughout his career, including Chief Medical Officer at Aimmune Therapeutics, Alvine Pharmaceuticals and Sunesis Pharmaceuticals. Previously Dr. Adelman served as Vice President of Clinical Operations and Biometrics at Pharmacyclics, and as a Clinical Scientist at Genentech where he was involved in the early development of omalizumab and bevacizumab. Dr. Adelman has also led the development of other therapies for celiac disease and food allergy. He began his career as an Assistant Professor of Clinical Medicine in the Division of Allergy and Immunology at the University of California, San Francisco (UCSF), School of Medicine, where he was also Director of Clinical Allergy and Immunology. He is also currently an Adjunct Professor of Medicine at UCSF, where he has taught and practiced at for more than 34 years, remaining on the faculty upon entering industry. He has also served on the editorial boards of the Journal of Clinical Immunology and Clinical Immunology, and as a clinical advisor to multiple biopharmaceutical companies. Dr. Adelman holds a bachelor’s degree in biology from the University of California, Berkeley, and earned his M.D. from the University of California, Davis. Inducement Grant In connection with the appointment of Dr. Tucker as its Chief Medical Officer, on June 12, 2023, Jasper granted Dr. Tucker an option to purchase 400,000 shares of voting common stock (the “Option”). This inducement award was granted pursuant to the Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and as amended and restated on June 2, 2023 (the “Plan”), and was granted as an inducement material to Dr. Tucker’s employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option is $1.62. The Option will vest over four years, with 25% of the total number of shares vesting on June 12, 2024 and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Dr. Tucker’s continued service to Jasper on each vesting date. Jasper is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Jasper Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at www.jaspertherapeutics.com. Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its therapeutic potential to address diseases such as urticaria, myelodysplastic syndromes as well as a conditioning agent and Jasper’s expectations regarding advancing and expanding its development program for briquilimab into chronic treatment indications such as CSU and LR-MDS, briquilimab’s promise in multiple disease states and advancing briquilimab toward its next clinical milestones and phase of development and Jasper’s ability to realize briquilimab’s potential. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent Quarterly Reports on Form 10-Q . If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com Lauren Barbiero (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com